Cells were seeded in 96-well plates at 2,000–10,000 cells per well, depending on the cell line. For single-agent dose response assays,
furamidine (Tocris, #5202) or
MS023 (Tocris, #5713) was added at the indicated concentrations using a
D300e Digital Dispenser (Tecan) or by manual serial dilution, with DMSO treatment as a negative control. After 7 days, cell viability was measured with the
CellTiter-Glo Luminescent Cell Viability Assay (Promega, #G7571) and normalized to DMSO control wells. For experiments evaluating combined AR and PRMT1 inhibition, cells were treated with a combination of
furamidine (Tocris) and
enzalutamide (Selleck) doses as indicated. After 7 days, cell viability was measured by CellTiter-Glo and normalized to DMSO wells. Drug synergy was evaluated with a Bliss independence model using Combenefit v2.021 (Di Veroli et al., 2016 (
link)).
Tang S., Sethunath V., Metaferia N.Y., Nogueira M.F., Gallant D.S., Garner E.R., Lairson L.A., Penney C.M., Li J., Gelbard M.K., Abou Alaiwi S., Seo J.H., Hwang J.H., Strathdee C.A., Baca S.C., AbuHammad S., Zhang X., Doench J.G., Hahn W.C., Takeda D.Y., Freedman M.L., Choi P.S, & Viswanathan S.R. (2022). A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer. Cell reports, 38(8), 110417.